Reata Lays Commercial Path For Skyclarys With First-Ever Friedreich’s Ataxia Nod
Executive Summary
The company forecasts an addressable US patient market that comprises 90% of the total Friedreich’s population of 5,000 based on a broad label covering patients aged 16 and older.
You may also be interested in...
Biogen’s Skyclarys Seals Important Next Step With EU Approval
Friedreich’s ataxia is particularly prevalent in Europe, and the company hopes to replicate the fast US uptake for Skyclarys there.
Biogen Buys Time For Leqembi Ramp-Up With Reata Acquisition
By agreeing to pay $7.3bn for Reata and its Friedrich’s ataxia drug Skyclarys, “recalibrating” Biogen can be more patient with launches of Alzheimer’s drug Leqembi and ALS therapy Qalsody.
PTC Misses Phase III In Friedrich Ataxia, But Isn’t Giving Up
Pointing to data showing benefit in patients who completed 72 weeks of therapy, PTC thinks vatiquinone still could be viable for pediatric FA patients. Restructuring won’t affect Upstaza.